Strengthens Company’s Expertise in Discovery and Research Reagents
BOSTON, MA -- July 19, 2006 -- PerkinElmer Inc., (NYSE: PKI), a global technology leader in Health Sciences and Photonics, today announced that Dr. Richard Eglen has joined the Company as vice president and general manager, discovery and research reagents for PerkinElmer’s Life & Analytical Sciences unit. In this position, Eglen is responsible for developing and executing PerkinElmer’s discovery and research reagents business strategy. This will involve growing the business through innovative sales initiatives, aggressive new product development and greater international expansion.
Eglen joins PerkinElmer from DiscoveRx, where he held the positions of chief scientific officer and executive vice president for research and development. Prior to that, Eglen worked for more than 20 years in several executive positions within the pharmaceutical, diagnostic and biotech industries.
“Richard brings both strong expertise in technology and drug discovery, as well as proven leadership abilities to PerkinElmer,” said Robert F. Friel, president, PerkinElmer Life and Analytical Sciences. “He will be instrumental in consolidating our position as the recognized industry leading provider of high-quality reagents and scientific expertise to researchers. These skills are increasingly important to research universities and pharmaceutical companies throughout the entire drug discovery process.”
“I am thrilled to join PerkinElmer because of the strength of its molecular medicine team, the breadth of the product portfolio and the depth of scientific experience,” said Eglen, whose expertise is in bringing innovative solutions to meet a variety of customer needs. “I look forward to furthering the company’s cellular approach to drug discovery assays and multiplexing technologies, including developing the successful acquisition of Agilix Corporation and the strategic partnership with the Luminex Corporation.”
Eglen has a Ph.D. in Molecular Pharmacology from Trent University in Nottingham, United Kingdom. He has been published in more than 250 scientific papers and books and holds several patents, many of which focus on key drug discovery targets such as GPCRs, kinases and ion channels. He also holds several patents relating to novel technologies for enabling drug discovery and other types of research. Eglen serves on numerous journal editorial boards and is a board member of the Society for BioMolecular Sciences (SBS).
Factors Affecting Future Performance
This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as "believes," "intends," "anticipates," "plans," "expects," “projects,” “forecasts,” "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
Other Information
Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging. Photonics markets include sensors and specialty lighting.